Metacrine is an emerging biotech company focused on developing best-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases. Metacrine’s lead program is focused on the Farnesoid X Receptor (FXR) and is based on a novel non-bile acid chemical scaffold. The lead molecule is expected to enter clinical development in early 2018.